StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Acquired In-Process R&D & Asset Acquisition Charges by Quarter

Acquired In-Process R&D (IPR&D) & Asset Acquisition Charges ($M) ($M)

QuarterlyAnnual

Merck Acquired In-Process R&D & Asset Acquisition Charges: $5,271M in Q2 2026.

Latest, Q2 2026
5,271
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
20 quarters
Since Q3 2021
Sources
15
Documents cited below

Where the Q2 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 10-Q (filed 2026-08-07) ↗

Reported in Form 10-Q / 10-K Cash Flow & Collaborative Arrangements Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAcquired In-Process R&D (IPR&D) & Asset Acquisition Charges ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20265,271–Form 10-Q (filed 2026-08-07) ↗
Q1 2026Mar 31, 20268,540–Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 20250-100.0%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 20250-100.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20250–Form 10-Q (filed 2026-08-07) ↗
Q1 2025Mar 31, 20250-100.0%Form 10-Q (filed 2026-05-04) ↗
Q4 2024Dec 31, 2024700-93.1%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 20242,100–Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 20240–Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 2024656-45.0%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 202310,217–Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 20230–Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-05) ↗
Q1 2023Mar 31, 20231,192–Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-03) ↗

Cite this data

StockData. (2026). Merck Acquired In-Process R&D & Asset Acquisition Charges ($M), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rd-iprd-acq-charges

See every metric in the Merck KPI table. Data updated Oct 26, 2026.